462 related articles for article (PubMed ID: 11306471)
1. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
[TBL] [Abstract][Full Text] [Related]
2. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
Osman S; Luthra SK; Brady F; Hume SP; Brown G; Harte RJ; Matthews JC; Denny WA; Baguley BC; Jones T; Price PM
Cancer Res; 1997 Jun; 57(11):2172-80. PubMed ID: 9187117
[TBL] [Abstract][Full Text] [Related]
3. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.
Hicks KO; Pruijn FB; Baguley BC; Wilson WR
J Pharmacol Exp Ther; 2001 Jun; 297(3):1088-98. PubMed ID: 11356933
[TBL] [Abstract][Full Text] [Related]
4. Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Haldane A; Finlay GJ; Hay MP; Denny WA; Baguley BC
Anticancer Drug Des; 1999 Jun; 14(3):275-80. PubMed ID: 10500502
[TBL] [Abstract][Full Text] [Related]
5. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
Spicer JA; Finlay GJ; Baguley BC; Velea L; Graves DE; Denny WA
Anticancer Drug Des; 1999 Feb; 14(1):37-45. PubMed ID: 10363026
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography.
Saleem A; Harte RJ; Matthews JC; Osman S; Brady F; Luthra SK; Brown GD; Bleehen N; Connors T; Jones T; Price PM; Aboagye EO
J Clin Oncol; 2001 Mar; 19(5):1421-9. PubMed ID: 11230487
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Spicer JA; Gamage SA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1997 Jun; 40(12):1919-29. PubMed ID: 9191970
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
Deady LW; Kaye AJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1997 Jun; 40(13):2040-6. PubMed ID: 9207945
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of phenanthrene-derived carboxamides as cytotoxic agents.
Cherubim P; Deady LW; Dorkos M; Quazi NH; Baguley BC; Denny WA
Anticancer Drug Des; 1993 Dec; 8(6):429-38. PubMed ID: 8286011
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biodistribution and micro-PET imaging of radiolabeled antimitotic agent T138067 analogues.
Fei X; Zheng QH; Wang JQ; Stone KL; Martinez TD; Miller KD; Sledge GW; Hutchins GD
Bioorg Med Chem Lett; 2004 Mar; 14(5):1247-51. PubMed ID: 14980675
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Bridewell DJ; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
[TBL] [Abstract][Full Text] [Related]
14. Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man.
Brady F; Luthra SK; Brown G; Osman S; Harte RJ; Denny WA; Baguley BC; Jones T; Price PM
Appl Radiat Isot; 1997 Apr; 48(4):487-92. PubMed ID: 9106990
[TBL] [Abstract][Full Text] [Related]
15. Synthetic approaches and bio-distribution studies of [11C]methyl-phenidate.
Patt M; Solbach C; Wüllner U; Blocher A; Stahlschmidt A; Gündisch D; Kovar KA; Machulla HJ
J Pharm Pharm Sci; 2007; 10(2):312s-320s. PubMed ID: 17718934
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
Foster BJ; Wiegand RA; LoRusso PM; Baker LH
Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
[TBL] [Abstract][Full Text] [Related]
19. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 4'-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging.
Toyohara J; Kumata K; Fukushi K; Irie T; Suzuki K
J Nucl Med; 2006 Oct; 47(10):1717-22. PubMed ID: 17015909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
